MTOR and prostate carcinoma: Moreover, activation of the AMPK/mTOR signaling pathway with rapamycin inhibited EMT and proliferation by increasing epithelial marker expression (e.g., E-cadherin) and reducing mesenchymal marker expression in prostate cancer cells.